Share capital and share based payments - Disclosure of Closing Balance of Share-Based Payment Arrangements (Details)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12 Months Ended |
|
|
Jul. 25, 2025
EUR (€)
shares
€ / shares
|
Nov. 13, 2024
EUR (€)
shares
€ / shares
shares
|
Aug. 01, 2024
EUR (€)
shares
€ / shares
shares
|
Jun. 10, 2024
EUR (€)
shares
€ / shares
shares
|
Feb. 15, 2024
EUR (€)
shares
€ / shares
shares
|
Dec. 21, 2023
EUR (€)
shares
€ / shares
|
Dec. 16, 2022
EUR (€)
shares
€ / shares
|
Dec. 12, 2022
EUR (€)
shares
€ / shares
|
Oct. 03, 2022
EUR (€)
shares
€ / shares
|
Oct. 01, 2021
EUR (€)
shares
€ / shares
|
Jul. 22, 2021
EUR (€)
shares
€ / shares
|
Aug. 05, 2020
EUR (€)
shares
€ / shares
|
Apr. 29, 2019
EUR (€)
shares
€ / shares
|
Sep. 20, 2017
EUR (€)
shares
€ / shares
|
Oct. 21, 2016
EUR (€)
shares
€ / shares
|
Jul. 01, 2015
EUR (€)
shares
€ / shares
|
Apr. 27, 2015
EUR (€)
shares
€ / shares
|
Jul. 16, 2014
EUR (€)
shares
€ / shares
|
Jul. 17, 2013
EUR (€)
shares
€ / shares
|
Dec. 31, 2025
shares
|
Dec. 31, 2024
shares
|
Dec. 31, 2023
shares
|
Dec. 31, 2022
shares
|
| AGA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,701,358
|
6,559,158
|
5,203,063
|
4,677,173
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
220,500
|
2,952,204
|
2,341,793
|
|
| AGAP Management 2016-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,200
|
1,200
|
1,200
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
156,000
|
156,000
|
156,000
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 year
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000
|
|
|
|
|
2,000
|
2,000
|
2,000
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
130
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 10.87
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40.00%
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 911
|
|
|
|
|
|
|
|
|
| AGAP Employees 2016-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,878
|
2,048
|
2,063
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
244,140
|
266,240
|
268,190
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 year
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,486
|
|
|
|
|
2,486
|
2,486
|
2,486
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
130
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 10.87
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40.00%
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 911
|
|
|
|
|
|
|
|
|
| AGAP 2016-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,000
|
3,000
|
|
| AGA New Members 2017-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
|
|
|
|
3 years
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
|
|
|
|
|
|
25,000
|
25,000
|
25,000
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
€ 5.74
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
€ 5.74
|
|
|
|
|
|
|
|
|
|
|
| AGA Perf Employees 2019-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| AGA Perf Management 2019-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| AGA Bonus 2020-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| AGA Perf Employees 2020-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
|
|
|
3 years 6 months
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
769,202
|
|
|
|
|
|
|
|
766,650
|
766,650
|
766,650
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
€ 2.94
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
|
|
45.00%
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
€ 2.94
|
|
|
|
|
|
|
|
|
|
|
|
| AGA Perf Management 2020-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
|
|
|
3 years 6 months
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
710,000
|
|
|
|
|
|
|
|
710,000
|
710,000
|
710,000
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
€ 2.94
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
|
|
45.00%
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
€ 2.94
|
|
|
|
|
|
|
|
|
|
|
|
| AGA Bonus 2021-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
|
|
1 year
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
125,748
|
|
|
|
|
|
|
|
|
125,748
|
125,748
|
125,748
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
€ 3.43
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
€ 3.43
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA Perf Employees 2021-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
819,300
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
819,300
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
|
3 years 6 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
1,066,600
|
|
|
|
|
|
|
|
|
|
1,066,600
|
1,066,600
|
1,066,600
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
€ 1.76
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
€ 1.76
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA Perf Management 2021-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
480,000
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
480,000
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
|
3 years 6 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
610,000
|
|
|
|
|
|
|
|
|
|
610,000
|
610,000
|
610,000
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
€ 1.76
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
€ 1.76
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA Bonus 2022-1 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
1 year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
128,061
|
|
|
|
|
|
|
|
|
|
|
128,061
|
128,061
|
128,061
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
€ 3.89
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
€ 3.89
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA Perf Employees 2022-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1,072,500
|
1,173,500
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1,072,500
|
1,173,500
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
3 years 1 month 6 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
1,371,500
|
|
|
|
|
|
|
|
|
|
|
|
1,371,500
|
1,371,500
|
1,371,500
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
€ 1.39
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
€ 1.39
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA Perf Management 2022-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
550,000
|
550,000
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
550,000
|
550,000
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
3 years 1 month 6 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
550,000
|
|
|
|
|
|
|
|
|
|
|
|
550,000
|
550,000
|
550,000
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
€ 1.39
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
€ 1.39
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA New Members 2023-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
25,000
|
25,000
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
25,000
|
25,000
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
25,000
|
25,000
|
|
| AGA Perf Employees 2023-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
895,000
|
1,273,750
|
1,399,000
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
895,000
|
1,273,750
|
1,399,000
|
|
| Vesting period (years) |
|
|
|
|
|
3 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
1,403,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,403,500
|
1,403,500
|
1,403,500
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
€ 1.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
€ 1.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA Perf Management 2023-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
525,000
|
750,000
|
750,000
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
525,000
|
750,000
|
750,000
|
|
| Vesting period (years) |
|
|
|
|
|
3 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
750,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
750,000
|
750,000
|
750,000
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
€ 1.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
€ 1.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA New Members 2024-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
25,000
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
25,000
|
|
|
| Vesting period (years) |
|
|
|
|
3 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
25,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
25,000
|
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
€ 2.31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
€ 2.31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA "Plan Epargne Entreprise" 2024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
|
|
| Number of free shares granted (in shares) |
|
|
|
68,744
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
68,744
|
68,744
|
|
|
| Share entitlement per free share (in shares) |
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
€ 2.45
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
€ 2.45
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA Perf Management 2024-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150,000
|
150,000
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150,000
|
150,000
|
|
|
| Vesting period (years) |
|
|
2 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
150,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150,000
|
150,000
|
|
|
| Share entitlement per free share (in shares) |
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
€ 2.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
€ 2.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA employees 2024-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
277,080
|
368,760
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
277,080
|
368,760
|
|
|
| Vesting period (years) |
|
3 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
370,560
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
370,560
|
370,560
|
|
|
| Share entitlement per free share (in shares) |
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
€ 1.62
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
€ 1.62
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA Perf Employees 2024-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
858,900
|
1,162,900
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
858,900
|
1,162,900
|
|
|
| Vesting period (years) |
|
3 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
1,162,900
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,162,900
|
1,162,900
|
|
|
| Share entitlement per free share (in shares) |
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
€ 1.87
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
€ 1.87
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA Perf Management 2024-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
600,000
|
975,000
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
600,000
|
975,000
|
|
|
| Vesting period (years) |
|
3 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
975,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
975,000
|
975,000
|
|
|
| Share entitlement per free share (in shares) |
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
€ 1.87
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
€ 1.87
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA Management 2024-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
200,000
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
200,000
|
|
|
| Vesting period (years) |
|
3 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
200,000
|
|
|
| Share entitlement per free share (in shares) |
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
€ 1.62
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
€ 1.62
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGA Employees 2025-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
164,300
|
|
|
|
| BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133,260
|
167,460
|
242,460
|
250,820
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133,260
|
167,460
|
242,460
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,000
|
0
|
50,000
|
|
| BSA 2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 years
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
237,500
|
237,500
|
237,500
|
237,500
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
| Exercise price (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 2.36
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 2.45
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.83%
|
|
|
|
|
| Average life of BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years 6 months
|
|
|
|
|
| Risk-free interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.42%
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0.87
|
|
|
|
|
| BSA 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
75,000
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
75,000
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 years
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150,000
|
|
150,000
|
150,000
|
150,000
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
| Exercise price (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 8.65
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 6.85
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
46.72%
|
|
|
|
|
|
| Average life of BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years 6 months
|
|
|
|
|
|
| Risk-free interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.00%
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 2.51
|
|
|
|
|
|
| BSA 2015-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
70,000
|
70,000
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
70,000
|
70,000
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 years
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70,000
|
|
|
70,000
|
70,000
|
70,000
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
| Exercise price (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 9.59
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 13.65
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
54.08%
|
|
|
|
|
|
|
| Average life of BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years 6 months
|
|
|
|
|
|
|
| Risk-free interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.25%
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 6.59
|
|
|
|
|
|
|
| BSA 2015-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
14,200
|
14,200
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
14,200
|
14,200
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 years
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,200
|
|
|
|
14,200
|
14,200
|
14,200
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
| Exercise price (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 14.05
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 13.64
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
47.83%
|
|
|
|
|
|
|
|
| Average life of BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years 6 months
|
|
|
|
|
|
|
|
| Risk-free interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.25%
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 4.73
|
|
|
|
|
|
|
|
| BSA 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37,000
|
37,000
|
37,000
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37,000
|
37,000
|
37,000
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
|
|
|
|
|
2 years
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
37,000
|
|
|
|
|
|
37,000
|
37,000
|
37,000
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
| Exercise price (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 11.00
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 10.41
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
61.74%
|
|
|
|
|
|
|
|
|
|
| Average life of BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
6 years
|
|
|
|
|
|
|
|
|
|
| Risk-free interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
0.20%
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0.57
|
|
|
|
|
|
|
|
|
|
| BSA 2022-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,260
|
8,260
|
8,260
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,260
|
8,260
|
8,260
|
|
| Vesting period (years) |
|
|
|
|
|
|
2 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
40,000
|
|
|
|
|
|
|
|
|
|
|
|
|
40,000
|
40,000
|
40,000
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 2.31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 1.31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Average life of BSA |
|
|
|
|
|
|
5 years 6 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk-free interest rate |
|
|
|
|
|
|
2.40%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 1.21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BSA 2023-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38,000
|
38,000
|
38,000
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38,000
|
38,000
|
38,000
|
|
| Vesting period (years) |
|
|
|
|
|
|
2 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
50,000
|
50,000
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 2.26
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 1.24
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
45.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Average life of BSA |
|
|
|
|
|
|
5 years 6 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk-free interest rate |
|
|
|
|
|
|
2.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
€ 1.24
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BSA-2025-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
0
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
0
|
0
|
|
| Vesting period (years) |
2 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
80,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,000
|
|
|
|
| Share entitlement per free share (in shares) |
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in EUR per share) | € / shares |
€ 0.64
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
€ 0.98
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected volatility |
45.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Average life of BSA |
5 years 6 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk-free interest rate |
2.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected dividends | € |
€ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
€ 0.98
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BSAAR |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1,045,722
|
1,045,722
|
1,105,072
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1,045,722
|
1,045,722
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| BSAAR 2011 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
650,000
|
650,000
|
650,000
|
|
| BSAAR 2012 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
146,050
|
146,050
|
146,050
|
|
| BSAAR 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclosure of terms and conditions of share-based payment arrangement [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of other equity instruments outstanding in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1,045,722
|
1,045,722
|
|
| Number of other equity instruments exercisable in share-based payment arrangement (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1,045,722
|
1,045,722
|
|
| Vesting period (years) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 years
|
|
|
|
|
|
|
|
| Number of free shares granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,050,382
|
|
|
|
1,050,382
|
1,050,382
|
1,050,382
|
|
| Share entitlement per free share (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
| Exercise price (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 7.20
|
|
|
|
|
|
|
|
| Grant date share fair value (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 13.77
|
|
|
|
|
|
|
|
| Expected volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41.00%
|
|
|
|
|
|
|
|
| Average life of BSA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10 years
|
|
|
|
|
|
|
|
| Risk-free interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.22%
|
|
|
|
|
|
|
|
| Expected dividends | € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 0
|
|
|
|
|
|
|
|
| Fair value per BSA (in EUR per share) | € / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ 1.15
|
|
|
|
|
|
|
|